A study led by researchers at St. Jude Children’s Research Hospital shows that microbial cell-free DNA sequencing can predict bloodstream infections in children with leukemia days before the infection is apparent.
The ASCERTAIN-V phase I/II clinical trial, which evaluated the first all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive induction chemotherapy, demonstrated favorable response rates and survival with expected myelosuppressive effects.
